ZA200108016B - Pyrazolobenzodiazephines as CDK2 inhibitors. - Google Patents

Pyrazolobenzodiazephines as CDK2 inhibitors.

Info

Publication number
ZA200108016B
ZA200108016B ZA200108016A ZA200108016A ZA200108016B ZA 200108016 B ZA200108016 B ZA 200108016B ZA 200108016 A ZA200108016 A ZA 200108016A ZA 200108016 A ZA200108016 A ZA 200108016A ZA 200108016 B ZA200108016 B ZA 200108016B
Authority
ZA
South Africa
Prior art keywords
pyrazolobenzodiazephines
cdk2 inhibitors
cdk2
inhibitors
Prior art date
Application number
ZA200108016A
Other languages
English (en)
Inventor
Qingjie Ding
Jin-Jun Liu
Vincent Stewart Madison
Giacomo Pizzolato
Chung-Chen Wei
Peter Michael Wovkulich
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ZA200108016B publication Critical patent/ZA200108016B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/22—Sulfur atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA200108016A 1999-04-21 2001-09-29 Pyrazolobenzodiazephines as CDK2 inhibitors. ZA200108016B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13037099P 1999-04-21 1999-04-21

Publications (1)

Publication Number Publication Date
ZA200108016B true ZA200108016B (en) 2003-03-26

Family

ID=22444382

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200108016A ZA200108016B (en) 1999-04-21 2001-09-29 Pyrazolobenzodiazephines as CDK2 inhibitors.

Country Status (33)

Country Link
US (3) US6440959B1 (ko)
EP (1) EP1185529B1 (ko)
JP (1) JP3746680B2 (ko)
KR (1) KR100481757B1 (ko)
CN (2) CN1196703C (ko)
AR (1) AR023542A1 (ko)
AT (1) ATE279413T1 (ko)
AU (1) AU768667B2 (ko)
BR (1) BR0009887A (ko)
CA (1) CA2367704C (ko)
CO (1) CO5170444A1 (ko)
CZ (1) CZ20013738A3 (ko)
DE (1) DE60014893T2 (ko)
DK (1) DK1185529T3 (ko)
ES (1) ES2228522T3 (ko)
HK (1) HK1046278B (ko)
HR (1) HRP20010742A2 (ko)
HU (1) HUP0300318A3 (ko)
IL (1) IL145764A0 (ko)
JO (1) JO2248B1 (ko)
MA (1) MA26782A1 (ko)
NO (1) NO20015065D0 (ko)
NZ (1) NZ514523A (ko)
PE (1) PE20010054A1 (ko)
PL (1) PL200933B1 (ko)
PT (1) PT1185529E (ko)
RU (1) RU2249593C2 (ko)
SI (1) SI1185529T1 (ko)
TR (1) TR200103016T2 (ko)
TW (1) TW585866B (ko)
WO (1) WO2000064900A1 (ko)
YU (1) YU73101A (ko)
ZA (1) ZA200108016B (ko)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2309209T3 (es) * 2001-11-13 2008-12-16 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 1,4-benzodiazepinas sustituidas y uso de las mismas para el tratamiento del cancer.
FR2847253B1 (fr) * 2002-11-19 2007-05-18 Aventis Pharma Sa Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant
WO2004076424A1 (en) * 2003-02-27 2004-09-10 Abbott Laboratories Heterocyclic kinase inhibitors
CN101899049A (zh) * 2004-10-13 2010-12-01 霍夫曼-拉罗奇有限公司 二取代吡唑并苯并二氮杂*类
EP1940410A1 (en) * 2005-10-14 2008-07-09 F.Hoffmann-La Roche Ag Regimen of administration for 5-(2-chlorophenyl)-1 ,2-dihydro-7-fluoro-8-methoxy-3-methyl-pyrazolo [3, 4.-b] [1, 4] benzodiazepine
EP2081921B1 (en) 2006-07-10 2010-09-08 PAION UK Limited Short-acting benzodiazepine salts and their polymorphic forms
KR20100073454A (ko) * 2008-12-23 2010-07-01 국립암센터 트란스글루타미나제 억제제로 사용되는 신규한 피라졸로디아제핀계 화합물, 이의 제조방법 및 이를 포함하는 조성물
EP2305647A1 (en) 2009-09-18 2011-04-06 PAION UK Limited Process for preparing 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4 H-imidazo[1,2-a][1,4]benzodiazepine-4-yl] propionic acid methyl ester or the benzene sulfonate salt thereof, and compounds useful in that process
EP2450039A1 (en) 2010-11-08 2012-05-09 PAION UK Ltd. Dosing regimen for sedation with CNS 7056 (Remimazolam)
US9321737B2 (en) * 2012-02-02 2016-04-26 Senex Biotechnology Inc CDK8-CDK19 selective inhibitors and their use in anti-metastatic and chemopreventative methods for cancer
CN103288828A (zh) * 2012-02-24 2013-09-11 中国科学院大连化学物理研究所 一种合成手性二氢-6H-吲哚并[2,1-c][1,4]-苯并二氮杂卓的方法
CN103288830A (zh) * 2012-02-24 2013-09-11 中国科学院大连化学物理研究所 一种合成手性二氢-5H-吡咯并[2,1-c][1,4]-苯并二氮杂卓的方法
CN102603743B (zh) * 2012-02-24 2014-05-28 南京天易生物科技有限公司 抗肿瘤的氮杂苯并[f]薁衍生物其制备方法及其用途
AR094963A1 (es) 2013-03-04 2015-09-09 Ono Pharmaceutical Co Reacción de oxidación excelente en el índice de conversión
CN106608877B (zh) * 2015-10-21 2018-11-13 新发药业有限公司 一种依鲁替尼中间体4-氨基-3-（4-苯氧基）苯基-1H-吡唑并[3,4-d]嘧啶的制备方法
WO2018083051A1 (en) * 2016-11-01 2018-05-11 F. Hoffmann-La Roche Ag 1,3-dihydro-1,4-benzodiazepine-2-thiones for the treatment of cns related diseases
CN108218868B (zh) * 2016-12-13 2019-02-19 南京药捷安康生物科技有限公司 多激酶抑制剂化合物、其晶型及用途
CN109020980B (zh) * 2017-06-09 2020-11-20 华东师范大学 一类抗肿瘤作用的吡唑并嘧啶二氮*衍生物
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
WO2020223558A1 (en) * 2019-05-01 2020-11-05 Incyte Corporation Tricyclic amine compounds as cdk2 inhibitors
AR119765A1 (es) 2019-08-14 2022-01-12 Incyte Corp Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
WO2021072232A1 (en) 2019-10-11 2021-04-15 Incyte Corporation Bicyclic amines as cdk2 inhibitors
US20230212167A1 (en) * 2020-05-08 2023-07-06 Transthera Sciences (Nanjing), Inc. Method for synthesizing anti-tumor compound and intermediates thereof
TW202237585A (zh) 2020-11-27 2022-10-01 瑞士商瑞森製藥公司 Ｃｄｋ抑制劑
WO2022149057A1 (en) 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Cdk inhibitors
CN115322196A (zh) * 2021-05-10 2022-11-11 药捷安康(南京)科技股份有限公司 多激酶抑制剂的药物组合物及其用途
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
WO2024030399A2 (en) * 2022-08-02 2024-02-08 Lab1636, Llc Use of a gaba-a pam for reduction of tactile hypersensitivity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0929553B1 (en) 1996-10-02 2005-03-16 Novartis AG Pyrimidine derivatives and processes for the preparation thereof
US6350786B1 (en) * 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers

Also Published As

Publication number Publication date
TR200103016T2 (tr) 2002-04-22
HRP20010742A2 (en) 2002-12-31
NO20015065L (no) 2001-10-18
NO20015065D0 (no) 2001-10-18
WO2000064900A1 (en) 2000-11-02
HK1046278B (zh) 2005-08-12
CN1603314A (zh) 2005-04-06
AU4748000A (en) 2000-11-10
CO5170444A1 (es) 2002-06-27
JP2002543081A (ja) 2002-12-17
BR0009887A (pt) 2002-01-22
CA2367704A1 (en) 2000-11-02
US20020183514A1 (en) 2002-12-05
PL200933B1 (pl) 2009-02-27
PL354405A1 (en) 2004-01-12
DE60014893T2 (de) 2005-10-13
JP3746680B2 (ja) 2006-02-15
KR20010112435A (ko) 2001-12-20
JO2248B1 (en) 2004-10-07
US6440959B1 (en) 2002-08-27
MA26782A1 (fr) 2004-12-20
EP1185529A1 (en) 2002-03-13
CN1279029C (zh) 2006-10-11
HUP0300318A2 (hu) 2003-06-28
DK1185529T3 (da) 2005-02-07
CN1196703C (zh) 2005-04-13
HUP0300318A3 (en) 2004-11-29
SI1185529T1 (en) 2005-02-28
KR100481757B1 (ko) 2005-04-11
CZ20013738A3 (cs) 2002-08-14
PE20010054A1 (es) 2001-02-07
EP1185529B1 (en) 2004-10-13
US6916923B2 (en) 2005-07-12
CA2367704C (en) 2008-06-17
ATE279413T1 (de) 2004-10-15
HK1046278A1 (en) 2003-01-03
DE60014893D1 (de) 2004-11-18
AU768667B2 (en) 2003-12-18
YU73101A (sh) 2004-05-12
NZ514523A (en) 2003-11-28
IL145764A0 (en) 2002-07-25
ES2228522T3 (es) 2005-04-16
US20040198976A1 (en) 2004-10-07
US6838558B2 (en) 2005-01-04
TW585866B (en) 2004-05-01
AR023542A1 (es) 2002-09-04
RU2249593C2 (ru) 2005-04-10
CN1348455A (zh) 2002-05-08
PT1185529E (pt) 2005-02-28

Similar Documents

Publication Publication Date Title
ZA200108016B (en) Pyrazolobenzodiazephines as CDK2 inhibitors.
ZA200109890B (en) Metalloprotease inhibitors.
ZA200108735B (en) Renin inhibitors.
IL148614A0 (en) Pteridinones as kinase inhibitors
GB9900416D0 (en) Inhibitors
MXPA01013362A (es) Anticuerpos de humano, anti-alfavbeta3 recombinantes, °cidos nucleicos que codifican a los mismos y metodos de uso.
ZA200206386B (en) Kinase inhibitors.
ZA200000894B (en) 4-Phenyl-pyridine derivatives.
ZA991975B (en) Enzyme inhibitors.
ZA200200477B (en) 2-pyrazolin-5-ones.
HK1054384A1 (en) 4-Pyrimidinyl-n-acyl-l-phenylalanines.
HK1045299A1 (en) Cell proliferation inhibitors.
ZA200202537B (en) Pour-on-formulations.
HK1046411A1 (en) 5-Phenyl-pyrimidine derivatives.
HK1053470A1 (en) 4-Pyridinyln-acyl-l-phenylalanines.
MXPA02005067A (es) Composicion inhibidora de la corrosion.
ZA200110053B (en) Factor via inhibitors.
IL148275A0 (en) Substituted 3-phenyl-5-alkoxy-1, 3, 4-oxdiazol-2-ones- and their use as lipase inhibitors
GB9924522D0 (en) Enzyme inhibitors
HK1042695A1 (zh) 蛋白酶抑制劑
GB0030284D0 (en) Enzyme inhibitors
MXPA01011285A (es) Derivados de tio-oxindol.
ZA200204581B (en) Nitro-sulfobenzamides.
ZA200206528B (en) Pyrimidine-4-one derivatives as LDL-PLA2 inhibitors.
HK1031254A1 (en) Tachogragh.